News

Tuesday
Jun022015

Initiation of Phase I clinical trial

MinervaX announced today that the company has initiated a Phase I clinical trial for its GBS vaccine candidate GBS-NN. The Phase I trial will enrol up to 310 healthy adult women in two parts, Part A, which is a safety and dose-escalation trial in up to 70 women, and Part B, which is an extended safety and dose confirmation trial in up to 240 women.

Press release
Statement from Professor Paul Heath, UK
Statement from Group B Strep Association, US
Wednesday
Jan082014

Equity and Loan Financing

MinervaX announces that the company has raised DKK 22 million (EUR 3 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment, and a Syndication Loan from The Danish Growth Foundation (VækstFonden).

Press release

Wednesday
Jan082014

FP7 Grant

MinervaX announces that the NeoStrep consortium, consisting of Lund University (Sweden), MinervaX ApS (Denmark), CiToxLAB A/S (Denmark), and BioKinetic Europe Ltd. (UK), has been awarded EUR 6 million in funding under the European Commission FP7 Programme HEALTH, for the development of a novel innovative Group B Streptococcal Vaccine candidate, owned by MinervaX.

Press release

Monday
Aug222011

Eurostar grant

MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the development of a LIPODEL adjuvant formulation of the NN GBS vaccine. Total grant budget amounts to 730,000 EUR.

Press release

Saturday
Jun112011

Technology Foundation grant

MinervaX announces the award of a grant from The Danish National Advanced Technology Foundation together with The State Serum Institute and University of Copenhagen for the development and testing of a CAF Adjuvant formulation of the NN GBS vaccine as well as a Chlamydia vaccine candidate. The total grant budget amounts to 29.6 mDKK (3.9 mEUR).

Press release